Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

2 weeks ago

PolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or death after colorectal surgery vs. standard …